- N-Acetyl-L-leucine
-
- $0.00 / 25kg
-
2026-05-15
- CAS:1188-21-2
- Min. Order: 1kg
- Purity: 97.5%-102.5%; AJI
- Supply Ability: 20 TONS
- N-Acetyl-L-leucine
-
- $10.00 / 1kg
-
2026-05-15
- CAS:1188-21-2
- Min. Order: 1kg
- Purity: 97.50%～102. 50%
- Supply Ability: 20 tons
|
| | N-Acetyl-L-leucine Basic information |
| | N-Acetyl-L-leucine Chemical Properties |
| Melting point | 187-190 °C(lit.) | | alpha | -24.5 º (c=4, MeOH) | | Boiling point | 303.86°C (rough estimate) | | density | 1.1599 (rough estimate) | | refractive index | -22 ° (C=5, EtOH) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO (Slightly), Ethanol (Slightly), Water (Slightly, Heated) | | pka | 3.67±0.10(Predicted) | | form | Crystalline Powder | | color | White | | Optical Rotation | [α]25/D 23±3°, c = 2 in ethanol | | Water Solubility | 0.81 g/100 mL (20 ºC) | | BRN | 1724849 | | Major Application | peptide synthesis | | InChI | 1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1 | | InChIKey | WXNXCEHXYPACJF-ZETCQYMHSA-N | | SMILES | CC(C)C[C@H](NC(C)=O)C(O)=O | | CAS DataBase Reference | 1188-21-2(CAS DataBase Reference) | | NIST Chemistry Reference | L-leucine, n-acetyl-(1188-21-2) | | EPA Substance Registry System | L-Leucine, N-acetyl- (1188-21-2) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 24/25-36-26 | | WGK Germany | 3 | | TSCA | TSCA listed | | HazardClass | IRRITANT | | HS Code | 29241900 | | Storage Class | 11 - Combustible Solids |
| | N-Acetyl-L-leucine Usage And Synthesis |
| Chemical Properties | White crystalline powder | | Uses | N-Acetyl-L-(-)-leucine is used in the preparation of small molecule inhibitors of anti-apoptotic Bcl-2 family proteins. Also used in the preparation of amphiphilic copolymers involving hydrophobic amino acid and oligopeptide side chains for optical tumor imaging in vivo. | | Definition | ChEBI: The N-acetyl derivative of L-leucine. | | reaction suitability | reaction type: C-H Activation
reaction type: solution phase peptide synthesis
reagent type: catalyst
reaction type: Peptide Synthesis | | in vivo | Levacetylleucine (60 mg/kg, i.v., administration on days 1, 2 and 3 for 15 days) decreases the postural imbalance scores and accelerates the course of postural compensation induced by UL in rats[3].
Levacetylleucine (100 mg/kg, oral gavage, administration daily for 28 days) attenuates cortical cell death afer traumatic brain injury (TBI) in N-Acetyl-L-leucine-treated TBI mouse cortices[4].
| Animal Model: | Male Sprague-Dawley rats (mean 400±20 g, age 3 months) after chemical UL[3] | | Dosage: | 60 mg/kg | | Administration: | i.v., 15 days | | Result: | Significantly decreased the postural imbalance scores on 7 day and accelerated the course of postural compensation by about 6 days in rats. |
| Animal Model: | C57/BL6 mice[4] | | Dosage: | 100 mg/kg | | Administration: | oral gavage, administration daily for 1-28 days | | Result: | Did not afect food intake and body weight in mice. |
| Animal Model: | N-Acetyl-L-leucine-treated TBI mouse cortices[4] | | Dosage: | 100 mg/kg | | Administration: | oral gavage, administration daily for 28 days | | Result: | Prevented cortical cell death which peaks at early time points (day 1) afer TBI in N-Acetyl-L-leucine-treated TBI mouse cortices. |
| | IC 50 | Human Endogenous Metabolite |
| | N-Acetyl-L-leucine Preparation Products And Raw materials |
|